Short-term efficacy of tacrolimus ointment and impact on quality of life

Yasuto Kondo, Yoichi Nakajima, Ryo Komatsubara, Makiko Kato, Noriko Hirata, Haruko Matuyama, Michiko Kakami, Ikuya Tsuge, Yukihiro Ohya, Atsuo Urisu

研究成果: Article

9 引用 (Scopus)

抄録

Background: Topical calcineurin inhibitor (TCI) was reported to be an effective therapeutic agent for patients with atopic dermatitis (AD), for not only improving clinical findings but also for reducing pruritus. Recently in Japan tacrolimus ointment (0.03%) as a TCI was approved for use in children aged ≥2 years. There have been no reports, however, on the impact of TCI on quality of life (QOL) in pediatric AD in Japan. The purpose of the present study was therefore to evaluate the efficacy of tacrolimus ointment (0.03%) in the short-term and the impact on patient QOL. Methods: A total of 30 pediatric patients with AD, whose skin problems were not sufficiently controlled by mid-high potency topical glucocorticosteroids, were enrolled. Efficacy was assessed on score of cutaneous findings, pruritus, sleeping disorder, and QOL. Results: Three patients discontinued because of skin burning (n = 1), generalized herpes infection (n = 1), and feeling of lack of efficacy (n = 1), leaving a final total of 27 patients who were evaluated. Significant improvements in clinical findings, pruritus, and sleeplessness were observed within 1 week of treatment and consequently each QOL category was also improved. These improvements continued for the duration of the study. Conclusions Tacrolimus ointment therapy is rapidly effective for not only clinical symptoms (cutaneous findings, pruritus and sleeplessness) but also in QOL of AD pediatric patients aged 2 years.

元の言語English
ページ(範囲)385-389
ページ数5
ジャーナルPediatrics International
51
発行部数3
DOI
出版物ステータスPublished - 01-06-2009

Fingerprint

Tacrolimus
Ointments
Atopic Dermatitis
Pruritus
Quality of Life
Skin
Sleep Initiation and Maintenance Disorders
Pediatrics
Japan
Proxy
Emotions
Therapeutics
Infection
Calcineurin Inhibitors

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

これを引用

Kondo, Yasuto ; Nakajima, Yoichi ; Komatsubara, Ryo ; Kato, Makiko ; Hirata, Noriko ; Matuyama, Haruko ; Kakami, Michiko ; Tsuge, Ikuya ; Ohya, Yukihiro ; Urisu, Atsuo. / Short-term efficacy of tacrolimus ointment and impact on quality of life. :: Pediatrics International. 2009 ; 巻 51, 番号 3. pp. 385-389.
@article{144b372747524281a1e83d1cbf8a49b9,
title = "Short-term efficacy of tacrolimus ointment and impact on quality of life",
abstract = "Background: Topical calcineurin inhibitor (TCI) was reported to be an effective therapeutic agent for patients with atopic dermatitis (AD), for not only improving clinical findings but also for reducing pruritus. Recently in Japan tacrolimus ointment (0.03{\%}) as a TCI was approved for use in children aged ≥2 years. There have been no reports, however, on the impact of TCI on quality of life (QOL) in pediatric AD in Japan. The purpose of the present study was therefore to evaluate the efficacy of tacrolimus ointment (0.03{\%}) in the short-term and the impact on patient QOL. Methods: A total of 30 pediatric patients with AD, whose skin problems were not sufficiently controlled by mid-high potency topical glucocorticosteroids, were enrolled. Efficacy was assessed on score of cutaneous findings, pruritus, sleeping disorder, and QOL. Results: Three patients discontinued because of skin burning (n = 1), generalized herpes infection (n = 1), and feeling of lack of efficacy (n = 1), leaving a final total of 27 patients who were evaluated. Significant improvements in clinical findings, pruritus, and sleeplessness were observed within 1 week of treatment and consequently each QOL category was also improved. These improvements continued for the duration of the study. Conclusions Tacrolimus ointment therapy is rapidly effective for not only clinical symptoms (cutaneous findings, pruritus and sleeplessness) but also in QOL of AD pediatric patients aged 2 years.",
author = "Yasuto Kondo and Yoichi Nakajima and Ryo Komatsubara and Makiko Kato and Noriko Hirata and Haruko Matuyama and Michiko Kakami and Ikuya Tsuge and Yukihiro Ohya and Atsuo Urisu",
year = "2009",
month = "6",
day = "1",
doi = "10.1111/j.1442-200X.2008.02741.x",
language = "English",
volume = "51",
pages = "385--389",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "3",

}

Kondo, Y, Nakajima, Y, Komatsubara, R, Kato, M, Hirata, N, Matuyama, H, Kakami, M, Tsuge, I, Ohya, Y & Urisu, A 2009, 'Short-term efficacy of tacrolimus ointment and impact on quality of life', Pediatrics International, 巻. 51, 番号 3, pp. 385-389. https://doi.org/10.1111/j.1442-200X.2008.02741.x

Short-term efficacy of tacrolimus ointment and impact on quality of life. / Kondo, Yasuto; Nakajima, Yoichi; Komatsubara, Ryo; Kato, Makiko; Hirata, Noriko; Matuyama, Haruko; Kakami, Michiko; Tsuge, Ikuya; Ohya, Yukihiro; Urisu, Atsuo.

:: Pediatrics International, 巻 51, 番号 3, 01.06.2009, p. 385-389.

研究成果: Article

TY - JOUR

T1 - Short-term efficacy of tacrolimus ointment and impact on quality of life

AU - Kondo, Yasuto

AU - Nakajima, Yoichi

AU - Komatsubara, Ryo

AU - Kato, Makiko

AU - Hirata, Noriko

AU - Matuyama, Haruko

AU - Kakami, Michiko

AU - Tsuge, Ikuya

AU - Ohya, Yukihiro

AU - Urisu, Atsuo

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Background: Topical calcineurin inhibitor (TCI) was reported to be an effective therapeutic agent for patients with atopic dermatitis (AD), for not only improving clinical findings but also for reducing pruritus. Recently in Japan tacrolimus ointment (0.03%) as a TCI was approved for use in children aged ≥2 years. There have been no reports, however, on the impact of TCI on quality of life (QOL) in pediatric AD in Japan. The purpose of the present study was therefore to evaluate the efficacy of tacrolimus ointment (0.03%) in the short-term and the impact on patient QOL. Methods: A total of 30 pediatric patients with AD, whose skin problems were not sufficiently controlled by mid-high potency topical glucocorticosteroids, were enrolled. Efficacy was assessed on score of cutaneous findings, pruritus, sleeping disorder, and QOL. Results: Three patients discontinued because of skin burning (n = 1), generalized herpes infection (n = 1), and feeling of lack of efficacy (n = 1), leaving a final total of 27 patients who were evaluated. Significant improvements in clinical findings, pruritus, and sleeplessness were observed within 1 week of treatment and consequently each QOL category was also improved. These improvements continued for the duration of the study. Conclusions Tacrolimus ointment therapy is rapidly effective for not only clinical symptoms (cutaneous findings, pruritus and sleeplessness) but also in QOL of AD pediatric patients aged 2 years.

AB - Background: Topical calcineurin inhibitor (TCI) was reported to be an effective therapeutic agent for patients with atopic dermatitis (AD), for not only improving clinical findings but also for reducing pruritus. Recently in Japan tacrolimus ointment (0.03%) as a TCI was approved for use in children aged ≥2 years. There have been no reports, however, on the impact of TCI on quality of life (QOL) in pediatric AD in Japan. The purpose of the present study was therefore to evaluate the efficacy of tacrolimus ointment (0.03%) in the short-term and the impact on patient QOL. Methods: A total of 30 pediatric patients with AD, whose skin problems were not sufficiently controlled by mid-high potency topical glucocorticosteroids, were enrolled. Efficacy was assessed on score of cutaneous findings, pruritus, sleeping disorder, and QOL. Results: Three patients discontinued because of skin burning (n = 1), generalized herpes infection (n = 1), and feeling of lack of efficacy (n = 1), leaving a final total of 27 patients who were evaluated. Significant improvements in clinical findings, pruritus, and sleeplessness were observed within 1 week of treatment and consequently each QOL category was also improved. These improvements continued for the duration of the study. Conclusions Tacrolimus ointment therapy is rapidly effective for not only clinical symptoms (cutaneous findings, pruritus and sleeplessness) but also in QOL of AD pediatric patients aged 2 years.

UR - http://www.scopus.com/inward/record.url?scp=66549088739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66549088739&partnerID=8YFLogxK

U2 - 10.1111/j.1442-200X.2008.02741.x

DO - 10.1111/j.1442-200X.2008.02741.x

M3 - Article

C2 - 19400811

AN - SCOPUS:66549088739

VL - 51

SP - 385

EP - 389

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 3

ER -